Aroa Biosurgery’s Symphony™: A New Hope for Diabetic Foot Ulcers?

Aroa Biosurgery Ltd ((AU:ARX)) announced an update on their ongoing clinical study.

Study Overview: Aroa Biosurgery Ltd is conducting a clinical study titled ‘A Multi-Center, Randomized Controlled Clinical Investigation Evaluating Wound Closure With Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers.’ The study aims to assess the safety and effectiveness of Symphony™ in treating chronic non-healing diabetic foot ulcers over a 12-week period, potentially offering a significant advancement in wound care management.

Intervention/Treatment: The study tests two interventions: the experimental Symphony™ treatment, which involves applying the Symphony™ device plus off-loading, and the Standard of Care (SOC) treatment, which uses a wound dressing comprising calcium alginate Fibracol plus off-loading. These interventions are designed to promote healing in diabetic foot ulcers.

Study Design: This interventional study employs a randomized, parallel assignment model with no masking, meaning it is open-label. The primary purpose is treatment-focused, aiming to compare the effectiveness of Symphony™ against standard care methods.

Study Timeline: The study began on August 23, 2023, and is currently recruiting participants. The primary completion and estimated study completion dates are not specified, but the last update was submitted on July 1, 2025. These dates are crucial for tracking progress and anticipating results.

Market Implications: The outcome of this study could significantly impact Aroa Biosurgery’s stock performance and investor sentiment, especially if Symphony™ proves more effective than current standard treatments. Success could position Aroa as a leader in the diabetic wound care market, potentially affecting competitors within this niche medical field.

The study is ongoing, with further details available on the ClinicalTrials portal.